VKTX
Viking Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.67
+6.06%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 94.0K | 431.0K | — | — | — |
| Gross Profit | (94.0K) | (431.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 586.2M | 345.0M | 101.6M | 63.8M | 54.2M |
| SG&A Expense | 62.4M | 48.4M | 49.3M | 37.0M | 16.1M |
| General & Admin Expense | 62.4M | 48.4M | 49.3M | 37.0M | 16.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 648.6M | 393.3M | 150.9M | 100.8M | 70.4M |
| Cost and Expenses | 648.6M | 393.3M | 150.9M | 100.8M | 70.4M |
| Operating Income (EBIT) | (648.6M) | (393.3M) | (150.9M) | (100.8M) | (70.4M) |
| Non-Operating | |||||
| Interest Income | 21.4M | 33.7M | 40.9M | 15.0M | 1.6M |
| Interest Expense | 88.0K | — | 94.0K | 88.0K | 59.0K |
| Net Interest Income | 21.3M | 33.7M | 40.8M | 14.9M | 1.5M |
| Other Non-Op Income/Expense | 21.4M | 33.7M | 41.0M | 14.9M | 1.5M |
| Non-Operating Income (excl Interest) | (21.5M) | (33.8M) | (41.1M) | (15.0M) | (1.5M) |
| EBT (Pre-Tax Income) | (627.2M) | (359.6M) | (110.0M) | (85.9M) | (68.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (627.2M) | (359.6M) | (110.0M) | (85.9M) | (68.9M) |
| Earnings from Cont. Ops | (627.2M) | (359.6M) | (110.0M) | (85.9M) | (68.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (627.2M) | (359.6M) | (110.0M) | (85.9M) | (68.9M) |
| Per Share | |||||
| Basic EPS | ($5.40) | ($3.19) | ($1.01) | ($0.91) | ($0.88) |
| Diluted EPS | ($5.40) | ($3.19) | ($1.01) | ($0.91) | ($0.88) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 118.0M | 112.7M | 109.0M | 94.3M | 76.8M |
| Diluted Shares Outstanding | 118.0M | 112.7M | 109.0M | 94.3M | 76.8M |
| Profitability Metrics | |||||
| EBITDA | (626.8M) | (359.2M) | (109.5M) | (85.5M) | (68.5M) |
| D&A | 336.0K | 431.0K | 346.0K | 292.0K | 291.0K |
| EBIT | (627.1M) | (359.6M) | (109.9M) | (85.8M) | (68.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026